Stay updated on Pembrolizumab in RCC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in RCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in RCC Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The renal cell carcinoma trial record is displayed with its study design, eligibility criteria, outcomes, results, and related documents, replacing the access-error page.
    Difference
    49%
    Check dated 2026-11-09T13:17:35.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The footer revision changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-02T12:50:25.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    An NIH announcement about the website transition and the use of “Super Intelligence” alongside “Artificial Intelligence” appears above the 403 error page.
    Difference
    1%
    Check dated 2026-10-26T15:48:02.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The footer revision number changes from v3.7.1 to v3.7.2 on the 403 Forbidden page.
    Difference
    0.2%
    Check dated 2026-10-19T21:40:31.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer now displays revision v3.7.1 instead of v3.7.0.
    Difference
    0.2%
    Check dated 2026-10-13T04:39:37.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The study record page displays a 403 Forbidden message and a Home link instead of study details.
    Difference
    0.5%
    Check dated 2026-10-05T20:51:35.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in RCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in RCC Clinical Trial page.